GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 13,700 shares, an increase of 23.4% from the November 30th total of 11,100 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 355,500 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GTBP. Roth Mkm initiated coverage on shares of GT Biopharma in a research note on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective on the stock. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd.

GT Biopharma Stock Performance

Shares of GTBP traded up $0.01 during midday trading on Tuesday, hitting $3.06. 29,343 shares of the stock traded hands, compared to its average volume of 447,347. The business’s 50 day moving average price is $2.89 and its two-hundred day moving average price is $2.58. GT Biopharma has a 1-year low of $1.72 and a 1-year high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.